We believe that by developing the user interface and leveraging the already tested algorithm, we would be able to meet the requirements under use case number 9 (MDT decision support).
Nevertheless, further validation of the algorithm would be necessary and our main question is, if that could be done within INCAREHEART as part of the proposal?
On page 25 of the Challenge Brief, when talking about FR10.1 – “Incorporation of patient held devices”, you say: “In relation to devices for monitoring, suppliers will be required to consider innovations from the HSMonitor PCP.”.
Could you please specify which innovations you refer to? To our knowledge the results of HSMonitor are not in the public domain, are they?
Please clarify further in detail what you mean by: “The financial compensation for IPRs must reflect the market value of the benefits received (i.e., the opportunity that the IPRs offer for commercial exploitation) and the risks assumed by the contractor (e.g. the cost of maintaining IPRs and bringing the products onto the market)” page 40, section 4.4 TD1.
Does this concern the financial compensation that shall be given after the project 2024 to the regions involved in the project?
Since both of the two solutions will be piloted in all five procurers’ regions in Phase 3 of the project (FAQ 13), and possibly multiple sites at each region (FAQ 32) this also requires adopting the solution for all sites. Roughly this can be broken up into the following tasks
Technical integration with the specific systems (e.g. EHR) at each site. Developing, deciding, and describing the process and workflow at each site, including the content (text and other media) that should be served by the solution. Technically setting up the solution to fit process and content from 2. For each of these tasks, which party […]